Advertisement
Canada markets close in 1 hour 47 minutes
  • S&P/TSX

    22,192.64
    +85.56 (+0.39%)
     
  • S&P 500

    5,254.87
    +6.38 (+0.12%)
     
  • DOW

    39,801.28
    +41.20 (+0.10%)
     
  • CAD/USD

    0.7388
    +0.0015 (+0.21%)
     
  • CRUDE OIL

    82.96
    +1.61 (+1.98%)
     
  • Bitcoin CAD

    96,030.99
    +3,248.55 (+3.50%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,242.30
    +29.60 (+1.34%)
     
  • RUSSELL 2000

    2,124.51
    +10.16 (+0.48%)
     
  • 10-Yr Bond

    4.2040
    +0.0080 (+0.19%)
     
  • NASDAQ

    16,385.60
    -13.92 (-0.08%)
     
  • VOLATILITY

    13.02
    +0.24 (+1.88%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6841
    +0.0036 (+0.53%)
     

Teva Pharm Q3 profit misses estimates, names new CFO

JERUSALEM, Nov 7 (Reuters) - Israel-based Teva Pharmaceutical Industries reported a larger-than-expected drop in third-quarter profit on Thursday and slightly raised its full year outlook.

The world's largest generic drugmaker earned 58 cents per diluted share excluding one-time items in the July-September period, down from 68 cents a year earlier. Revenue fell 6% to $4.26 billion.

Analysts had forecast Teva would earn 59 cents a share ex-items on revenue of $4.24 billion, according to I/B/E/S data from Refinitiv.

For 2019 it raised its forecast of adjusted EPS to $2.30-$2.50 from $2.20-$2.50 and revenue to $17.2-$17.4 billion from $17.0-$17.4 billion. Analysts are forecasting EPS of $2.38 on revenue of $17.18 billion.

Teva also named Eli Kalif as its new chief financial officer effective Dec. 22. (Reporting by Steven Scheer; Editing by Alex Richardson)